Online inquiry

IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11162MR)

This product GTTS-WQ11162MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IFNAR1 gene. The antibody can be applied in Diffuse scleroderma research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000629.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3454
UniProt ID P17181
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ11162MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12343MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MTIG-7192-A
GTTS-WQ10128MR IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LAG-525
GTTS-WQ11435MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-9447
GTTS-WQ162MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 1-26/3-67
GTTS-WQ11891MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MLN-1202
GTTS-WQ14495MR IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA RYI-018
GTTS-WQ13388MR IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PR-1594804
GTTS-WQ210MR IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 13C5.5
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW